{"id":"NCT03731182","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Children With Sickle Cell Disease (V114-023/PNEU-SICKLE)","officialTitle":"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Children With Sickle Cell Disease (PNEU-SICKLE)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-01-23","primaryCompletion":"2020-06-08","completion":"2020-06-08","firstPosted":"2018-11-06","resultsPosted":"2021-06-16","lastUpdate":"2021-06-16"},"enrollment":104,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"PREVENTION"},"conditions":["Pneumococcal Infections"],"interventions":[{"type":"BIOLOGICAL","name":"V114","otherNames":[]},{"type":"BIOLOGICAL","name":"Prevnar 13™","otherNames":[]}],"arms":[{"label":"V114","type":"EXPERIMENTAL"},{"label":"Prevnar 13™","type":"ACTIVE_COMPARATOR"}],"summary":"This study is designed to describe the safety, tolerability, and immunogenicity of V114 in children with sickle cell disease.","primaryOutcome":{"measure":"Percentage of Participants With a Solicited Injection-site Adverse Event","timeFrame":"Up to 14 days post-vaccination","effectByArm":[{"arm":"V114","deltaMin":4.3,"sd":0.9},{"arm":"Prevnar 13™","deltaMin":5.9,"sd":0.7}],"pValues":[]},"eligibility":{"minAge":"5 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":18},"locations":{"siteCount":19,"countries":["United States","Brazil","Colombia","Dominican Republic","Greece","Italy","Panama"]},"refs":{"pmids":["36383730"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":13,"n":69},"commonTop":["Injection site pain","Injection site swelling","Headache","Myalgia","Fatigue"]}}